CAR T-cell Therapy Market to Reach US$ 21.8 Bn by 2031, Industry Players Aim at Better Therapies for Patients with Hematological Malignancy and Solid Tumors: TMR Study

- Stakeholders working concertedly to widen the availability of chimeric antigen receptors (CAR) T-cell therapy has benefitted patient populations worldwide; players comply with stringent regulations to build up a lucrative product pipeline

- Growing clinical approval of CAR-T-cell-based therapies against high-grade B-cell lymphomas and acute lymphocytic leukemia (ALL) offers consistent growth opportunities to market players

ALBANY, N.Y., Oct. 11, 2021 /PRNewswire/ -- The growing clinical effectiveness of the treatment of chimeric antigen receptors (CAR) T-cell therapies in various hematological malignancies, acute lymphoblastic leukemia, and large B-cell lymphomas shapes the growth trajectories of the CAR T cell therapy market. Over the years, patients have witnessed increased clinical response and better disease remission in both relapsed and refractory diseases. Concurrently, the long-term safety and efficacy of the product have increased for advanced and metastatic cancers, thereby prolonging the relapse-free survival rates in patients.  

Considerable body of clinical studies in advanced phases have demonstrated their effectiveness in treating certain large B-cell lymphomas notably acute lymphocytic leukemia (ALL). Furthermore, extensive studies on the quality of life of patient populations, including adults and pediatric continue to enrich the landscape. During the COVID-19 pandemic, strides in telehealth services have worked in favor of the CAR T-cell therapy market. The global CAR T-cell therapy market valuation is projected to reach US$ 21.8 Bn by 2031.

Request Brochure of CAR T-cell Therapy Market Research Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=83242

Key Findings of CAR T-cell Therapy Market Study

• Regulatory Frameworks Support Safer and More Effective Therapies for Cancer: Growing compliance of biotech and pharmaceutical companies with stringent regulations for manufacturing CAR T-cells especially in the European Union (EU) and North America is continuously working to reduce the potential adverse effects in the patient population. Particularly, this has spurred phase I/II studies on harnessing the potential of advanced viral-based gene transfer methods and non-viral methods for developing therapies for B-cell malignancies.

Moreover, industry players focus on reducing the major toxicities associated with CAR T-cell therapies comprising cytokine release syndrome (CRS) and the neurotoxicity. Such developments continue to reflect in the growing number of approvals in key regions such as by the U.S. FDA., notes a TMR study on the global CAR T-cell therapy market.

Request for Analysis of COVID-19 Impact on CAR T-cell Therapy Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=83242

• Collaborations Gear toward Increasing Affordability of Therapies Globally: The cost of treatment is a key impediment to the adoption of the therapy. This hinders the clinical translation of the results of innovative therapeutic approaches in cancer immunology to benefit target populations. Especially, the gap is evident among patients with high-grade B-cell lymphomas. Industry players in partnership with governments in the CAR T-cell therapy market are relentlessly working to reduce the cost of the treatment in countries with constrained resources. A case in point is the Biotechnology Industry Research Assistance Council (BIRAC) whose efforts have boosted the financial backing for cancer immunotherapy programs in India.
• Diffuse Large B-cell Lymphoma (DLBCL) Emerge as Highly Lucrative Target Population: Hematological malignancies, notably diffuse large B-cell lymphoma (DLBCL), present players in the CAR T-cell therapy market with sizable revenue prospects during the forecast period, notes the TMR study. However, the realization of possibilities in the solid tumors is still in preliminary stages. Nonetheless, this undoubtedly presents a massive avenue for market players. The effective translation of CAR T-cell therapy to solid tumors is fraught with therapeutic limitations and challenges. The healthcare systems are constantly working to overcome these to extend the benefits of the therapies to the patients. New strategies using genetic engineering have been leveraged to eliminate tumor cells. 

Buy CAR T-cell Therapy Market Research Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=83242&ltype=S

CAR T-cell Therapy Market: Key Drivers

• The substantial contribution of hematologic malignancies (HMs) in global cancer burden has increasingly concerned the healthcare sector, policymakers, and the research community globally. This has spurred constant search for therapies with better outcomes particularly cancer immunotherapies. As a result, the industry has been witnessing a surge in phase I and II clinical studies in cancer immunology over the years, thus driving the evolution of the CAR T-cell therapy market.
• Recent advancements in gene modification technologies such as CRISPR/Cas9 and transfer of genes using DNA-based transposons have enabled researchers to explore novel approaches in cancer immunotherapies. This has extended the horizon for pharmaceutical and biotech companies in boosting their product pipeline toward approval by regulatory agencies.

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough, Request for Custom Research: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=83242

CAR T-cell Therapy Market: Competition Landscape

Some of the prominent players in the CAR T-cell therapy market are Bristol-Myers Squibb, Johnson & Johnson Services, Inc., Merck & Co., Inc., Gilead Sciences, Inc., Sorrento Therapeutics, Inc., Amgen, Inc., Novartis AG, bluebird bio, Inc., and Pfizer, Inc.

Global CAR T-cell Therapy Market: Segmentation

• CAR T-cell Therapy Market, by Product Type
• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Lisocabtagene Maraleucel
• Idecabtagene Vicleucel
• Others
• CAR T-cell Therapy Market, by Indication
• Acute Lymphocytic Leukemia
• Diffuse Large B-cell lymphoma
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Multiple Myeloma
• Others
• CAR T-cell Therapy Market, by End-user
• Hospitals
• Cancer Treatment Centers
• CAR T-cell Therapy Market, by Region
• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reports by Transparency Market Research: 

Cancer Immunotherapy Market: The global cancer immunotherapy market is prognosticated to encounter a high rate of development over the coming years, inferable from the rise in number of people suffering from different types of cancers. In 2015, the global cancer immunotherapy market was esteemed at US$37.50 bn. its revenue is anticipated to progress at an extremely solid CAGR of 14.6% inside a conjecture period from 2016 to 2024, the global cancer immunotherapy market is required to achieve US$124.88 bn before the finish of 2024.

Clinical Trials Market: Companies in the clinical trials market are following guidelines of the FDA to advance in processes. They are referring to FDA guidance about Severely Debilitating or Life-Threatening Hematologic Disorders (SDLTHDs) in patients. Companies are increasing efforts to fill in the gap between scientific and technical complexities of clinical trials.

Gene Therapy Market: Introduction of new production, availability of reimbursement together with high occurrences of cancer are estimated to propel growth of the global gene therapy market in the years to come. Gene therapy refers to an experimental technique, which utilizes genes for the prevention and treatment of various diseases.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact Us:

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Follow Us: Twitter | LinkedIn
Blog: https://tmrblog.com
Browse PR - https://www.transparencymarketresearch.com/pressrelease/car-t-cell-therapy-market.html

Logo: https://mma.prnewswire.com/media/1085206/Transparency_Market_Research_Logo.jpg